ArticleNpj viruses2026
Immunogenicity and protective efficacy of MERS CoV, NL140422, and HKU4 spike protein nanoparticle vaccines.
Article in Npj viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
While vaccines against Middle East respiratory syndrome coronavirus (MERS-CoV) have had substantial preclinical and clinical development, few vaccine candidates target other related viruses with potential for human spillover within the Merbecovirus subgenus, like NL140422 and HKU4. We designed nanoparticle vaccines displaying the spike ectodomains of MERS-CoV, NL140422, and HKU4 and evaluated their immunogenicity and protective efficacy in mice. All vaccines elicited high IgG antibody titers against the corresponding vaccine spike protein with moderate cross-binding to mis-matched spike proteins as well. Only the MERS-CoV spike protein induced detectable neutralizing antibodies against MERS-CoV. In human dipeptidyl peptidase 4 (hDPP4) transgenic mice, vaccination with MERS-CoV spike protein completely inhibited MERS-CoV replication in the lungs and nasal turbinates. Vaccination with NL140422 and HKU4 spike proteins provided partial but significant reductions of lung viral loads after MERS-CoV challenge, highlighting their utility as components of a future pan-Merbecovirus vaccine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.